Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia

Lynette Chee; Nora Lee; Andrew Grigg; Melissa Chen; Anthony Schwarer; Jeff Szer; Sumita Ratnasingam; Sonia Raj; Pohan Lukito; David Yeung; Timothy Hughes; Naranie Shanmuganathan

doi:10.1111/imj.16446

Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia

Lynette Chee
, Nora Lee
, Andrew Grigg
, Melissa Chen
, Anthony Schwarer
, Jeff Szer
, Sumita Ratnasingam
, Sonia Raj
, Pohan Lukito
, David Yeung
, Timothy Hughes
, Naranie Shanmuganathan

Blood Cancer Program

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real-world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib-pretreated cohort.

Original language	English
Pages (from-to)	1214-1218
Number of pages	5
Journal	Internal Medicine Journal
Volume	54
Issue number	7
DOIs	https://doi.org/10.1111/imj.16446
Publication status	Published or Issued - Jul 2024

Keywords

asciminib
chronic myeloid leukaemia
tyrosine kinase inhibitor

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1111/imj.16446

Cite this

@article{fb357abe7cf04da4a38916318ca6c792,

title = "Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia",

abstract = "Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real-world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib-pretreated cohort.",

keywords = "asciminib, chronic myeloid leukaemia, tyrosine kinase inhibitor",

author = "Lynette Chee and Nora Lee and Andrew Grigg and Melissa Chen and Anthony Schwarer and Jeff Szer and Sumita Ratnasingam and Sonia Raj and Pohan Lukito and David Yeung and Timothy Hughes and Naranie Shanmuganathan",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Internal Medicine Journal published by John Wiley \& Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.",

year = "2024",

month = jul,

doi = "10.1111/imj.16446",

language = "English",

volume = "54",

pages = "1214--1218",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "John Wiley and Sons Inc.",

number = "7",

}

TY - JOUR

T1 - Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia

AU - Chee, Lynette

AU - Lee, Nora

AU - Grigg, Andrew

AU - Chen, Melissa

AU - Schwarer, Anthony

AU - Szer, Jeff

AU - Ratnasingam, Sumita

AU - Raj, Sonia

AU - Lukito, Pohan

AU - Yeung, David

AU - Hughes, Timothy

AU - Shanmuganathan, Naranie

PY - 2024/7

Y1 - 2024/7

N2 - Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real-world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib-pretreated cohort.

AB - Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real-world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib-pretreated cohort.

KW - asciminib

KW - chronic myeloid leukaemia

KW - tyrosine kinase inhibitor

UR - https://www.scopus.com/pages/publications/85196184568

U2 - 10.1111/imj.16446

DO - 10.1111/imj.16446

M3 - Article

AN - SCOPUS:85196184568

SN - 1444-0903

VL - 54

SP - 1214

EP - 1218

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 7

ER -

Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this